National Comprehensive Cancer Network® (NCCN®)

NCCN Policy Summit Explores How COVID-19 Pandemic Can Lead to Improvements in Cancer Care

Virtual #NCCNPolicy summit convened by National Comprehensive Cancer Network addresses opportunities for improving oncology policy based on lessons from the coronavirus crisis

Newswise — PLYMOUTH MEETING, PA [June 15, 2021] — Today, the National Comprehensive Cancer Network® (NCCN®) hosted a virtual NCCN Policy Summit examining the impact of the past year on oncology policy in America. The program, “Defining the ‘New Normal’— 2021 and the State of Cancer Care in America Following 2020,” brought together a diverse group of experts to discuss the resumption of recommended screening and clinical trials, how to apply health innovations from the COVID-19 pandemic to cancer treatment, and what concrete steps can be taken to address the systemic inequalities that lead to disparities in outcomes.

“The medical community has proven that rapid, extraordinary progress can be made when we respond to a threat like the COVID-19 pandemic with the urgency, focus, and collaboration it demands,” said Crystal S. Denlinger, MD, FACP, Senior Vice President, Chief Scientific Officer, NCCN. “We have the opportunity to improve cancer treatment and research by not just reverting to pre-pandemic standards, but reimagining how we move care forward. We’ve learned a lot over the past year about how to do better when it comes to providing health care; now we must apply that knowledge to oncology.”

“Partnership drives equitable care, and the CMS Office of Minority health is committed to advancing collaboration for all our beneficiaries and consumers,” said LaShawn McIver, MD, MPH, Director, Centers for Medicare and Medicaid Services (CMS) Office of Minority Health. “The current public health emergency illuminates the barriers we’ve broken down, and those we still must overcome—particularly for people hard hit by health disparities. Opportunities like the NCCN Policy Summit underscore both the importance and breadth of collaboration needed across healthcare to advance equitable solutions.”  

The speakers and panelists presented some of the latest data on health trends over the past year, while cautioning that much of that research is still early and ongoing. Some key areas of focus included:

  • Reducing barriers that prevent people from getting recommended health screenings and care in a timely fashion;
  • Maintaining telehealth options wherever beneficial to patients (e.g. survivorship care);
  • Utilizing electronic health records (EHRs) as a patient/provider portal for communication;
  • Funding the resumption of the basic science research pipeline for clinical trials;
  • Leveraging real-world evidence to broaden knowledge beyond the typical clinical trial population;
  • Recognizing and addressing bias and lack of diversity in medical care providers; and
  • Addressing the social determinants of health that result in disparities in outcomes.

"Cancer Care in the United States has evolved in the face of a global pandemic,” said Timothy Kubal, MD, MBA, Senior Medical Director, Moffitt Cancer Center, Co-Chair of the NCCN Best Practices Committee. “Despite this evolution in practice and process, each day we continue to lose the lives of people we love. The purpose of policy change is to lead us somewhere different; to take us to a better place where those lives are saved instead of lost. Our world has changed; our policy cannot stay the same."

NCCN is actively involved in several initiatives addressing some of the issues discussed, such as:

  • Cancer Won’t Wait and Neither Should You: An endorsement of the safe resumption of cancer screening and treatment, jointly with the American Cancer Society and 75 other cancer organizations.
  • Elevating Cancer Equity: Recommendations to Reduce Racial Disparities in Access to Guideline Adherent Cancer Care, in collaboration with the American Cancer Society Cancer Action Network, and the National Minority Quality Forum
  • NCCN Best Practices Webinar Series: A series on COVID-19 and Cancer Center operations

Additional speakers included:

  • Murray Aitken, MBA, Executive Director, IQVIA Institute for Human Data Science
  • Jeff Allen, PhD, President and Chief Executive Officer, Friends of Cancer Research
  • Keysha Brooks-Coley, Vice President, Federal Advocacy and Strategic Alliances, ‎American Cancer Society Cancer Action Network
  • Jennifer Malin, MD, PhD, Chief Medical Officer, Oncology & Genetics, UnitedHealthcare

Additional quotes:

Sarah Alwardt, Vice President of Operations at Ontada says:

“Although we do not yet know the full impact of COVID-19, one clear outcome has been the massive public education on the importance of real-world evidence in clinical trials. We have now reached the tipping point in using real-world data to accelerate trial design and populations. We’ve demonstrated that this real-world evidence can be trusted and I hope that we ensure this momentum carries forward.”

Shonta Chambers, MSW, Executive Vice President of Health Equity Initiatives and Community Engagement, Patient Advocate Foundation says:

“As we think about elevating cancer equity, we can’t ignore the impact of the social determinants of health hindering people’s ability to access and adhere to cancer care. These determinants have political underpinnings that continue to perpetuate disparate outcomes among populations of color. We have to systematically assess social needs gaps in the content of healthcare delivery for all patients, and create sustainable partnership and collaborations with entities best positioned to respond to them locally and nationally. Healthcare outcomes are not limited to the four walls of the healthcare systems, we must account for the social context of one's healthcare and act on tangible solutions to respond to them. That is how we elevate cancer equity for everyone.”

Jennie Crews, MD, Vice President and Medical Director, SCCA Community and Network Programs, at Seattle Cancer Care Alliance says:

“The COVID-19 pandemic is driving rapid innovation in cancer care delivery which will continue to influence how cancer care evolves going forward. Seattle Cancer Care Alliance, like many of our peers across the nation, quickly adapted to incorporate the rapid pace of knowledge and data around COVID-19, modified clinical care and clinical trials, and addressed issues such as disparities in access to care. We experienced rapid and widespread adoption of virtual care for patient visits and monitoring, allowing SCCA to continue to provide care in ways that met patient needs through nearly 30,000 virtual visits.”

Gwen Darien, Executive Vice President for Patient Advocacy and Engagement, National Patient Advocate Foundation says:

“Two years ago, we were all talking about personalized medicine. As a result of the pandemic, I’m increasingly interested in talking about personal medicine. How do we create and maintain personal connections when the modern office visit is only 15 minutes? I spent much of my childhood waiting in the car while my dad—an internist in Milwaukee—made house calls. He knew his patients so well. Telehealth is still in its nascent form, so we have the opportunity to sculpt it into a contemporary house call, allowing health care providers to see the challenges and barriers patients face and the social context of their health.”

Pamela Kunz, MD, Vice Chief, Diversity Equity and Inclusion, Medical Oncology, Director for the Center for Gastrointestinal Cancers, Yale Cancer Center and Smilow Cancer Hospital says:

“In order for us to provide equitable patient care, we also need to achieve diversity and equity in our professional workforce. These are inextricably linked.”

Christopher Lathan, MD, MS, MPH, Chief Clinical Access and Equity Officer, Dana-Farber Cancer Institute says:

“What we’ve learned from the COVID experience is when we want to, we are able to recruit diverse patients to clinical trials. This shows that these barriers can be overcome with resources and willpower. If we really want to ensure our vulnerable patients are reengaging with preventive and diagnostic services, we must have the will and resources to support them appropriately.”

Andrea D. Willis, MD, MPH, FAAP, Senior Vice President and Chief Medical Officer, BlueCross BlueShield of Tennessee

"The COVID crisis taught us that we can make things happen when we all rally around a cause.  The call to reduce health disparities when it comes to cancer treatment and prevention is not a new one but the momentum we currently have to realize health equity requires a stronger response."

The next NCCN Virtual Policy Summit will take place on Thursday, September 9, and focus on ‘The Impact of Technology on Cancer Care in 2021.’ For more information, visit NCCN.org/summits and join the conversation with the hashtag #NCCNPolicy.

# # #

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.

 



Filters close

Showing results

110 of 6110
Released: 2-Aug-2021 6:05 PM EDT
Rethinking Remdesivir
University of California San Diego Health

UC San Diego researchers modify remdesivir, creating oral version that can be taken earlier in COVID-19 diagnoses. In cell and animal studies, revised drug proved effective and safe.

Newswise: Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Released: 2-Aug-2021 4:25 PM EDT
Researchers from Hackensack Meridian University Medical Center and Colleagues Develop New Model to Help Clinicians Predict Risk of Death in Patients Hospitalized with COVID-19
Hackensack Meridian Health

New COVID-19 40-day mortality risk model, published in The Public Library of Science ONE, has potential for use in patient treatment planning, comparisons of therapeutic strategies, and public-health preparations.

Released: 2-Aug-2021 4:05 PM EDT
Town Hall on Effectiveness of COVID-19 Vaccination in Immunosuppressed Patients Hosted by the American College of Rheumatology
American College of Rheumatology (ACR)

How effective COVID-19 vaccines have been in immunosuppressed and rheumatic disease patients remains an incompletely answered question. The American College of Rheumatology (ACR) has organized an expert panel to share what we are learning from real-world data and answer questions.

Released: 2-Aug-2021 2:00 PM EDT
CDC withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test does not mean the test failed
Newswise

Social media is now rife with claims about why the CDC is withdrawing its request for emergency use authorization for its COVID-19 PCR diagnostic test after December 2021.

Newswise: Existing Drug Is Shown to Inhibit Virus That Causes COVID-19
Released: 2-Aug-2021 1:30 PM EDT
Existing Drug Is Shown to Inhibit Virus That Causes COVID-19
Argonne National Laboratory

Scientists using the Advanced Photon Source have discovered that a drug used to fight tumors in animals might be effective against many types of coronaviruses, including SARS-CoV-2.

Released: 2-Aug-2021 11:25 AM EDT
Award-Winning Journalist and CDC Principal Investigator to Serve as ACR Convergence 2021 Keynote Speaker
American College of Rheumatology (ACR)

Convergence 2021, the annual meeting of the American College of Rheumatology (ACR), returns to a virtual meeting platform Nov. 1 - 10. This year’s meeting will include presentations from over 320 clinicians, researchers and health experts, including this year’s keynote speaker, Dr. Seema Yasmin.

Newswise: COVID-19: Small Sign of Hope as Vaccinations Rise
Released: 2-Aug-2021 10:45 AM EDT
COVID-19: Small Sign of Hope as Vaccinations Rise
Cedars-Sinai

As COVID-19 cases spike in Los Angeles and throughout the Golden State, driven by the spread of the delta variant among unvaccinated residents, there may be a small sign of hope: More people are finally getting their shot.

Newswise: New Evidence Shows the COVID-19 Delta Variant Rapidly Rising
Released: 31-Jul-2021 10:05 AM EDT
New Evidence Shows the COVID-19 Delta Variant Rapidly Rising
University of Miami Health System, Miller School of Medicine

The University’s coronavirus sequencing effort uncovered that there are several variants present in its patient population, but Delta is chief among them and easily transmitted. And its presence is likely triggering a local surge in the infectious disease. University of Miami researchers and physicians are seeing firsthand how rapidly the Delta variant of COVID-19 is spreading through the local population.

Released: 30-Jul-2021 2:05 PM EDT
Thinking Impaired in 60% of COVID-19 Survivors, Study Finds
University of Texas Health Science Center at San Antonio

In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference.


Showing results

110 of 6110

close
1.38567